Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from...

Related Keywords

Singapore ,Linkedin Invitae ,Swaroop Aradhya ,Saumya Jamuar Shekhar ,Invitae Corporation ,American College Of Medical Genetics ,Exchange Commission ,Institute Of Precision Medicine ,Uncertain Significance ,Hereditary Disease Genetic Testing ,Ashkenazi Jewish ,Pacific Islander ,Precision Medicine ,American College ,Medical Genetics ,Private Securities Litigation Reform Act ,Quarterly Report ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,